(Q36245711)

13 August 2017

1 reference

title

Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides (English)

1 reference

13 August 2017

Braun J

1

1 reference

13 August 2017

Baraliakos X

series ordinal

2

1 reference

13 August 2017

Brandt J

series ordinal

3

1 reference

13 August 2017

Sieper J

series ordinal

4

1 reference

13 August 2017

publication date

1 May 2005

1 reference

Scandinavian Journal of Rheumatology

13 August 2017

published in

1 reference

13 August 2017

volume

34

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

178-190

1 reference

Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Costs of ankylosing spondylitis in three European countries: the patient's perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Functional disability predicts total costs in patients with ankylosing spondylitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Results from an open-label extension study of etanercept in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Role of novel biological therapies in psoriatic arthritis: effects on joints and skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Treatment of reactive arthritis with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Successful treatment of SAPHO syndrome with infliximab: report of two cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Biological therapies in the spondyloarthritides--the current state

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

One-year open-label trial of thalidomide in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F03009740510026599

10.1080/03009740510026599

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference